Literature DB >> 16806299

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.

Joohyung Lee1, Vincenzo Di Marzo, Jonathan M Brotchie.   

Abstract

Although most commonly associated with actions at cannabinoid CB1 receptors on the extracellular surface of the plasma membrane, the endocannabinoid anandamide (AEA) is also transported into the cell, by the putative anandamide membrane transporter (AMT), and activates the vanilloid receptor 1 (TRPV1) at an intracellular site. AEA is then inactivated by fatty acid amide hydrolase (FAAH). As systemic administration of TRPV1 ligands reduces locomotor activity in normal rodents, we hypothesised that activation of TRPV1 by endocannabinoids could play a role in the control of voluntary movement and that such actions could be regulated by AMT and FAAH. Motor activity was assessed in normal, in reserpine-treated, and in reserpine-treated rats treated with L-DOPA. In normal rats, the TRPV1 agonist capsaicin (1 mg/kg) or the FAAH inhibitor URB597 (10 mg/kg) caused a significant reduction in movement in both the horizontal (locomotion) and vertical (rearing) planes (-45% and -53% respectively with capsaicin; -33% and -37% for URB597). Capsaicin-induced hypolocomotion was attenuated by the TRPV1 antagonist, capsazepine. There was no effect of capsaicin, URB597 or the AMT inhibitor OMDM-2 on motor activity in reserpine-treated rats. L-DOPA treatment of reserpine-treated rats elicited high levels of motor activity in both the horizontal and vertical planes. Horizontal activity was attenuated by capsaicin (1 mg/kg, -60%), but not by URB597 (10 mg/kg) or OMDM-2 (5 mg/kg). Vertical activity was attenuated by capsaicin (1 mg/kg, -61%) and by URB597 (10 mg/kg, -54%), but not by OMDM-2. These data suggest that activation of the TRPV1 system can suppress spontaneous locomotion in normal animals and modulates several L-DOPA-induced behaviours in reserpine-treated rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806299     DOI: 10.1016/j.neuropharm.2006.04.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  23 in total

1.  Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens.

Authors:  Brad A Grueter; Gabor Brasnjo; Robert C Malenka
Journal:  Nat Neurosci       Date:  2010-11-14       Impact factor: 24.884

2.  Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis.

Authors:  Andras Garami; Eszter Pakai; Daniela L Oliveira; Alexandre A Steiner; Samuel P Wanner; M Camila Almeida; Vladimir A Lesnikov; Narender R Gavva; Andrej A Romanovsky
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 3.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition.

Authors:  H-T Liao; H-J Lee; Y-C Ho; L-C Chiou
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  Prenatal corticosterone and adolescent URB597 administration modulate emotionality and CB1 receptor expression in mice.

Authors:  Chiara Ceci; Virginia Mela; Simone Macrì; Eva M Marco; Maria-Paz Viveros; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2013-12-06       Impact factor: 4.530

6.  TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.

Authors:  Jin H Nam; Eun S Park; So-Yoon Won; Yu A Lee; Kyoung I Kim; Jae Y Jeong; Jeong Y Baek; Eun J Cho; Minyoung Jin; Young C Chung; Byoung D Lee; Sung Hyun Kim; Eung-Gook Kim; Kyunghee Byun; Bonghee Lee; Dong Ho Woo; C Justin Lee; Sang R Kim; Eugene Bok; Yoon-Seong Kim; Tae-Beom Ahn; Hyuk Wan Ko; Saurav Brahmachari; Olga Pletinkova; Juan C Troconso; Valina L Dawson; Ted M Dawson; Byung K Jin
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

7.  Methanandamide blocks amphetamine-induced behavioral sensitization in rats.

Authors:  Bruce A Rasmussen; Ellen M Unterwald; Jae K Kim; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2009-10-30       Impact factor: 4.432

Review 8.  Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity.

Authors:  Sang R Kim; Young C Chung; Eun S Chung; Keun W Park; So Y Won; E Bok; Eun S Park; Byung K Jin
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

9.  Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats.

Authors:  Leigh V Panlilio; Carmen Mazzola; Julie Medalie; Britta Hahn; Zuzana Justinova; Filippo Drago; Jean Lud Cadet; Sevil Yasar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2008-11-18       Impact factor: 4.530

10.  Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

Authors:  Maria Grazia Morgese; Tommaso Cassano; Vincenzo Cuomo; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2007-08-22       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.